GlaxoSmithKline, Almirall deal

GlaxoSmithKline granted Almirall rights to develop and commercialize Veltin Gel clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin in Austria, the Czech Republic, Italy, the Netherlands, Poland, Slovakia, Spain and Mexico. Almirall had distribution rights to Toctino in select European countries and Mexico under a June 2010 deal with Basilea Pharmaceutica AG (SIX:BSLN, Basel, Switzerland). GSK’s Stiefel Laboratories Inc. subsidiary gained worldwide rights to Toctino under a June 2012 deal with Basilea and now has consolidated rights in Europe. Almirall will commercialize Veltin Gel and Altabax through its U.S. affiliate, Aqua Pharmaceuticals. ...